Pharma and a no-deal Brexit
Author: Dawn Southgate
“The pharmaceutical industry is responsible for the continuity of supply of medicines and ensuring they are compliant with regulatory regulations” says the European Medicines Agency (EMA). EU legislation states that the marketing authorisation holders of EU medicines must be located in the EU or EEA which means that those based in the UK must be transferred to the EU/EEA in order to retain authorisation. The EMA gives some advice to pharma companies before Britain leaves the EU this month or in the event of a no-deal Brexit.
European Pharmaceutical Review, Vol 24(1) February 2019, pp12-13
[First appeared in Cutting Edge, 13 March 2019]